Compare Infosys Limited (INFY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Recursion Pharmaceuticals Inc — how do they compare? Infosys Limited trades at $12.4 (market cap $50.32B), while Recursion Pharmaceuticals Inc trades at $3.34 (market cap $1.78B). The key difference: Infosys Limited is far larger — about 28.3× Recursion Pharmaceuticals Inc's market cap, and Infosys Limited pays a 4.17% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INFY | RXRX | |
|---|---|---|
Market Cap | $50.32B | $1.78B |
Sector | Technology | Health |
52-Week High | $20.22 | $6.79 |
52-Week Low | $10.49 | $2.84 |
Enterprise Value | $48.07B | $1.30B |
Dividend Yield | 4.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $12.53, up 1.38% today, with a bullish technical signal from moving averages. The company reported a Q1 2027 revenue miss but maintained strong operating margins of 21.1% and announced a CEO transition. Recent news highlights strategic AI collaborations, such as with Metsä Group and Sentara, driving digital transformation initiatives.
The outlook is mixed: robust profitability and AI growth offer upside, but lowered revenue guidance and competitive pressures pose risks. Analyst consensus is cautious with a $11.05 price target below the current price, suggesting limited near-term upside amid execution challenges.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
